Cleared Traditional

K233391 - cCeLL - In vivo (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K233391 · VPIX Medical, Inc. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2024
Decision
324d
Days
Class 2
Risk

K233391 is an FDA 510(k) clearance for the cCeLL - In vivo. Classified as Endoscope, Neurological (product code GWG), Class II - Special Controls.

Submitted by VPIX Medical, Inc. (Daejeon, KR). The FDA issued a Cleared decision on August 21, 2024 after a review of 324 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.1480 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Neurology review framework, consistent with the majority of Class II 510(k) submissions.

View all VPIX Medical, Inc. devices

Submission Details

510(k) Number K233391 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 02, 2023
Decision Date August 21, 2024
Days to Decision 324 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
176d slower than avg
Panel avg: 148d · This submission: 324d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code GWG Endoscope, Neurological
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.1480
Definition If The Device Is Reusable, Validated Reprocessing Instructions And Reprocessing Validation Data For This Device Type Must Be Included In A 510(k) Submission (82 Fr 26807, Available At Https://www.gpo.gov/fdsys/pkg/fr-2017-06-09/pdf/2017-12007.pdf).
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Consultant

MRC Global, LLC
Dawn N. Norman, MS

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - GWG Endoscope, Neurological

All 90
Devices cleared under the same product code (GWG) and FDA review panel - the closest regulatory comparables to K233391.
HJY VisualNext 3D Endoscopic Vision System
K243429 · Hjy Smart Medical Device Co., Ltd. · May 2025
AURORA® Surgiscope® System (ASX15/60)
K250752 · Integra LifeSciences Corporation · Apr 2025
Digital ClarusScope System, Digital NeuroPEN System
K223615 · Clarus Medical, LLC · Nov 2023
Aurora Surgiscope System
K232618 · Rebound Therapeutics Corporation · Oct 2023
Neuroblade System
K230125 · Clearmind Biomedical · Oct 2023
QEVO System
K232159 · Carl Zeiss Meditec, AG · Sep 2023